期刊文献+

Safety and efficacy of early administration of tirofiban in patientswith acute ST-segment elevation myocardial infarction undergoingprimary percutaneous coronary intervention: a meta-analysis 被引量:12

原文传递
导出
摘要 Background Tirofiban has been widely used as an adjunctive pharmacologic agent for revascularization in patients undergoing percutaneous coronary intervention, and the outcomes appear attractive. However, the potential benefits from early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction(STEMI) undergoing primary percutaneous coronary intervention(PPCI) remain unclear.Methods We conducted a search in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to September 2012 without language restriction. A total of eight randomized trials(n=1 577 patients) comparing early(emergency department or ambulance) versus late(catheterization laboratory) administration of tirofiban in STEMI patients undergoing PPCI were included in this meta-analysis. Risk ratio(RR) was computed from individual studies and pooled with random- or fixed-effect models.Results There were no differences in post-procedural Thrombolysis In Myocardial Infarction(TIMI) flow grade 3 and Corrected TIMI Frame Count(RR=1.02, 95% confidence interval(CI): 0.99–1.05, P=0.18; weighted mean difference(WMD)=–0.93, 95% CI: –5.37–3.52, P=0.68, respectively) between the two groups. Similarly, there were no significant differences in the incidence of 30-day mortality(RR=1.69, 95% CI: 0.69–4.13, P=0.25) and re-myocardial infarction(RR=0.71, 95% CI: 0.21–2.35, P=0.57) between early and late administration of tirofiban. As to the safety end points, no significant difference was observed in hospital minor bleeding(RR=1.08, 95% CI: 0.54–2.14, P=0.83) and hospital and 30-day major bleeding between the two groups(RR=0.98, 95% CI: 0.46–2.10, P=0.96; RR=1.32, 95% CI: 0.59–2.97, P=0.49, respectively).Conclusions Early administration of tirofiban in patients undergoing PPCI for STEMI was safe, but no beneficial effects on post-procedural angiographic or clinical outcomes could be identified as compared with late administration. Besides the negative finding, more high-quality randomized clinical trials are still needed to explore the efficacy of adequate, earlier administration of tirofiban in patients undergoing PPCI.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第6期1126-1132,共7页 中华医学杂志(英文版)
  • 引文网络
  • 相关文献

参考文献2

二级参考文献5

共引文献34

同被引文献63

引证文献12

二级引证文献135

;
使用帮助 返回顶部